Psychedelics
Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. […]
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States. The Centre of Excellence will model the “clinic of […]
Leading Microbiologist, Dr. Robert E.W. Hancock Appointed as Executive Chairman of Core One Labs
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One“) is pleased to announce the appointment of Dr. Robert E.W. Hancock as Executive Chairman of the Company, effective January 6, 2021. Dr. Hancock is an internationally renowned academic in Microbiology and Immunology – having bestowed upon him the title of UBC Killam Professor of Microbiology […]
EMPOWER CLINICS INC. (CBDT:CSE)(8EC:Frankfurt)(EPWCF:OTCQB) (“Empower“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce the successful launch of our KAI Saliva PCR Test (“KAI […]
MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand
Mind Medicine (MindMed) Inc. (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) (“MindMed”) is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the Underwriters’ over-allotment option (the “Offering”). In connection with the Offering, the Company issued 20,930,000 units of the Company (the “Units”) […]
Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing
Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (“Havn Life”) is pleased to announce that, further to its news release dated December 15, 2020, the Company has completed its previously announced bought deal public offering of 10,747,900 units (the “Units“), including 1,401,900 Units issued pursuant to the Underwriter’s (as defined below) over-allotment option which was exercised in full, […]
Red Light Holland Announces $5 Million Bought Deal Equity Financing
Red Light Holland Corp. (“Red Light Holland”) (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight […]
Emerging psychedelic drug development company Diamond Therapeutics has received new investment from the Ontario Brain Institute (OBI), a not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. An early believer in Diamond’s precision, low-dose approach to psychedelic therapies, OBI provided the company with funding in 2019. Now, OBI has more than […]
Red Light Holland Announces Increase in Bought Deal Equity Financing to $8.5 Million
Red Light Holland Corp. (“Red Light Holland”) (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight […]
Thoughtful Brands Announces Binding Letter of Intent for Reverse-Takeover of Franchise Cannabis
Thoughtful Brands Inc. (“TBI“) (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) and Franchise Cannabis Corp. (“FCC“) are pleased to announce that they have entered into a binding letter of intent (the “Letter of Intent“), dated January 6, 2021, to consummate a going-public transaction for FCC involving the reverse-takeover of TBI (the “Transaction“). The Transaction will involve the acquisition of all of […]
The MAPS-sponsored multi-site study will be the first of its kind assessing the viability of MDMA-assisted therapy to treat eating disorders, including Anorexia Nervosa and Binge Eating Disorder. TORONTO, Jan. 07, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, […]
Mydecine Innovations Group Shares Intellectual Property Update
Company files seven provisional patent applications with United States Patent and Trademark Office DENVER, Jan. 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced […]
Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board
La Jolla, California–(Newsfile Corp. – January 7, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific […]
Pure Extracts Now Listed on the OTC Markets Under the Symbol PRXTF
VANCOUVER, British Columbia, Jan. 07, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL)(OTC: PRXTF)(XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company is pleased to announce that the Company received trading approval from OTC Markets and is now trading on the OTC Market under the ticker symbol PRXTF. Pure Extracts CEO, Ben […]
NeonMind Appoints Trevor Millar as Chief Psychedelic Officer
Vancouver, British Columbia–(Newsfile Corp. – January 7, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind“), a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to announce that it has appointed Trevor Millar as Chief Psychedelic Officer of NeonMind as of January 6, 2021. NeonMind […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”) is pleased to announce the release of iSTRYM, the Company’s digital therapeutic tool, designed to provide close to real-time data regarding patient care, procedures and protocols, and other resources for therapists, clinicians, and patients with mental health concerns. “As a life sciences and […]
Lobe Sciences Announces Further Upsizing and Second Closing of Non-Brokered Private Placement
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the “Units“) from $2,700,000 to $3,445,847 (the “Offering“) and has completed a second and final tranche closing, raising gross proceeds of $1,118,747 (the “Second […]
Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp. (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health […]
CYBIN Provides Update on Patent Filings & Development of Therapeutics Program
Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to provide an update on its on its eight patent filings, which cover the Company’s novel therapeutics, delivery mechanisms and treatment regiments. Cybin’s updated corporate presentation will be available at www.cybin.com. The Company is also pleased to announce that it […]
COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021. George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, […]
Mindset Pharma Inc. (CSE: MSET) (“Mindset” or the “Company”), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds are […]
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University […]
Field Trip Health Ltd. Announces Closing of Bought Deal Financing
Field Trip Health Ltd. (“Field Trip” or the “Company”) (CSE: FTRP) (OTCBB: FTRPF), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriters’ over-allotment option (the “Offering“). In connection with […]
Psychedelic Wellness-Focused Company Delic Corp Announces Shep Gordon to Join Advisory Board
VANCOUVER, BC, Jan. 5, 2021 /CNW/ – Delic Corp. (“DELIC” or the “Company“) (CSE: DELC), a psychedelic wellness-focused company, is pleased to welcome Shep Gordon to the advisory board. Shep Gordon is an American talent manager, Hollywood film agent, and producer. Matt Stang, Founder of DELIC commented, “We are very excited to have Shep on board. His wealth of experience across multiple business’ […]
Novamind to Commence Trading (CSE:NM) on January 5th, 2021
Novamind Inc. (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic-assisted psychotherapy, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange under the symbol “NM” tomorrow, January 5, 2021. “Over the last 18 months, we have developed an industry-leading network of mental health clinics and […]
NeonMind Commences Trading Under CSE Ticker Symbol “NEON”
NeonMind completed its oversubscribed Initial Public Offering on December 30, 2020, for gross proceeds of $4,600,000. NeonMind is a psychedelic drug development company. It’s mission is to help people change their lives by changing their minds, through treatment with psychedelics. NeonMind’s initial focus is on one of the biggest health issues the world is facing […]
Nova Mentis Expands Psychedelic Drug Pipeline
VANCOUVER, BC, Dec. 29, 2020 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeruginascin. NOVA is currently developing C-GMP API […]
Neonmind To Start Trading On CSE Today
Neonmind Biosciences Inc.’s common shares today commenced trading on the Canadian Securities Exchange under the ticker symbol NEON. More information on NeonMind can be found at www.neonmindbiosciences.com. NeonMind Commences Trading Under CSE Ticker Symbol “NEON”To view an enhanced version of this image, please visit:https://orders.newsfilecorp.com/files/7646/71280_754b8cd704168a78_001full.jpg NeonMind completed its oversubscribed Initial Public Offering on December 30, 2020, […]
Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (“Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce the closing of the agreement to acquire Lawrence Park Health […]
Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF)(“NOVA”) is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing preclinical and clinical autism spectrum disorder […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
KetamineOne Capital is focused on consolidating medical clinics and becoming a North American leader in mental health treatments.
CaniBrands is a next-generation wellness products company that specializes in manufacturing innovative CBD (Cannabidiol) formulations for sports recovery and active living. CaniBrands products are trusted by professional athletes and backed by science. The company has a wide selection of products for sports recovery, energy, focus, pain and sleep. Along with sublingual oils, balms and creams, […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
